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Early Detection and Endovascular 
Intervention to Correct Dialysis 
Vascular Access Malfunction
Pedro Ponce and Ana Mateus
Abstract
Endovascular intervention in hemodialysis vascular access is among the most 
frequent interventions performed in an angiography suite. Vascular stenosis is the 
most prevalent lesion causing vascular access malfunction. Vascular access pathol-
ogy and the outcomes in response to endovascular treatment are quite different 
from the arterial territory. Treatment strategy must be integrated, multidisci-
plinary, and with a long-term perspective, as recurrence rates of malfunction are 
quite common. We will detail our experience managing an extremely busy vascular 
access center serving a population of 4000 dialysis patients, performing all endo-
vascular techniques in close coordination with the surgical team.
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1. Introduction
Endovascular interventions have substituted surgical repair as the primary 
treatment of failing or thrombosed vascular access (VA). Endovascular and surgical 
techniques, however, are complementary. Optimizing endovascular interventions 
of VA malfunction is a crucial component for a successful vascular access program. 
The identification and early treatment of stenosis are essential to prevent access 
thrombosis and ultimate failure.
Despite recent advances in endovascular techniques and devices, angioplasty 
continues to be the primary method for the treatment of access-related stenosis. 
Not all stenosis needs to be treated. When timely applied, angioplasty is a fast, easy, 
and safe procedure that can extend the patency of a hemodialysis graft or fistula.
The early detection and endovascular intervention to correct dialysis vascular access 
malfunction are reviewed in this chapter, describing the authors’ experience in a 
highly active Vascular Access Center in Lisbon, integrated in a large outpatient 
dialysis network. We will cover the following topics: (1) vascular access options and 
its selection, (2) vascular access morbidity and complications, (3) vascular access 
malfunction detection, (4) endovascular interventions to correct dialysis vascular 
access malfunction, and (5) endovascular intervention outcomes.
2. Vascular access options and its selection
The VA constitutes the interface between chronic kidney disease (CKD) patient 
and machine (the dialysis monitor); its function is a key factor that affects most 
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dialysis treatment quality indicators, such as dialysis dose and adequacy (Kt/V), 
substitution volume during hemodiafiltration, operating costs, and vital prognosis 
of the dialysis patient.
In this chapter, we deal only with long-term arteriovenous accesses:
A. The native AV fistula (nAVF), usually result from an end-to-side anastomosis 
of a vein to an artery, either at the wrist (distal fistula), most commonly a 
radio-cephalic fistula, or at the elbow/upper arm level (proximal fistula), in 
this position most commonly a brachiocephalic fistula, or a brachio-basilic 
fistula, this last one requiring a second procedure the transposition to the 
surface of the arterialized vein.
B. The arteriovenous graft (AVG), usually a second choice in patients not suitable 
for a nAVF fistula, has better mechanical strength, can be used earlier, and has 
lower primary failure rates when compared with nAVF, but has a much higher 
infection risk, a poorer primary long-term patency, and needs many more 
interventions to remain functional.
The VA dysfunction and its complications, such as low access flow (Qa), infec-
tion, loss of dialysis adequacy, or thrombosis, are the major single cause of hospi-
talization and morbidity requiring endovascular intervention, as well as one of the 
most important drivers of the total cost of an end-stage renal failure program.
Whenever a native arteriovenous fistula (AVF) can be built and is able to mature 
in no more than 8 weeks, it is considered the first and best choice as a vascular 
access. It results in higher long-term longevity and less thrombotic or infectious 
morbidity, needs fewer procedures for maintenance, and is overall a big life and 
money saver.
The nAVF, however, comes with its own set of disadvantages. There is a higher 
risk of primary failure (nonmaturation) up to 60% prior to cannulation, requiring 
frequent angiographic procedures to assist maturation [1–3]. Studies have shown 
that the primary failure rate is two times greater for fistulas (40%) than grafts 
(19%), with similar cumulative patency; in addition, the number of catheter days 
before AV access use was more than double in those using a fistula (81 days) than 
those with AV grafts (38 days); however, grafts require more angioplasties (1.4 vs. 
3.2 events) and thrombolysis (0.05 vs. 0.98 events) interventions per 1000 patient-
days [2, 4]. The risk of primary fistula failure is much higher for lower arm fistula 
(28%) than with upper arm fistula (20%), although these last ones produce more 
than 90% of all cephalic arch stenosis [1].
The secondary patency rates of AV grafts (total life span even if requiring 
several interventions to maintain its function) are on average around 3 years, all in 
all identical to AV fistulas, but those improved rates are achieved at the expense of 
three- to six-fold greater reintervention rates.
There has never been a randomized control trial (RCT) comparing different 
VA choices regarding mortality or other hard outcomes. All large observational 
trials compared accesses achieved as opposed to the accesses that were intended 
(as in intention to treat). As 25–60% of all AVFs created either fail or need several 
procedures to mature and the central venous catheter (CVC) group in most studies 
were people in whom AVF failed or CVC was chosen because of a predictable bad 
prognosis (age, congestive heart failure, short life expectancy, etc.), we really can-
not answer the question on which VA is the best. If we exclude patients that begin 
hemodialysis urgently, mortality between nAVF and CVC patients becomes identi-
cal. Using a decision analysis model (fed with data extracted from DOPPS 2, the 
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REDUCE FTM study, the DAC study, and CMS data) for choosing the best option 
for patients initiating hemodialysis (HD) with a CVC, a nAVF attempt strategy is 
associated with better survival and lower annual cost, but that advantage is progres-
sively lost in patients above 60 years or diabetics [5, 6].
Access malfunction is a source of tremendous emotional and physical suffering, 
dialysis treatments loss, low treatment adequacy, urgent need for a central catheter 
as a substitution access, and referral for new angiography or surgical procedures at 
huge costs.
In this chapter, we basically describe our experience on VA management in 
our dialysis network treating approximately 5000 patients in our Vascular Access 
Center (VAC) that performs more than 1000 VA surgeries and more than 1600 
endovascular interventions per year.
3. Vascular access morbidity and complications
The most common VA complications are failure to mature, persistently low Qa, 
suboptimal dialysis adequacy, pain, aneurysms, rupture/hemorrhage, infection, 
and thrombosis. Endovascular stenosis is the underlying lesion and the direct 
culprit behind most of these complications.
Neointimal hyperplasia is the common pathogenic mechanism inducing ste-
nosis, and stenosis is the underlying promoter of thrombosis. Stenotic plaques 
are composed of myofibroblasts (smooth muscle cells) surrounded by extracel-
lular matrix and macrophages. This cell proliferation begins in the adventitia and 
migrates toward the lumen of anastomotic areas or endothelial segments exposed 
to several stresses, such as surgical trauma, shear stress, wall stress, diameter and 
compliance mismatch, uremic endothelial dysfunction, and wall lesion secondary 
to repeated needle punctures.
Stenosis is necessary for thrombosis, but it is not enough. Only 30% of stenosis 
above 50% of lumen compromise will cause thrombosis in the next 6 months; we 
just do not know which ones. On the other hand, angioplasty induces accelerated 
NH with recurrent stenosis [7]. In 20% of the cases, recurrent stenosis occurs 
in 1 week and in 40% in 1 month [8], and although stenosis stenting may delay 
stenosis recurrence, it did not reduce the incidence of thrombosis [9].
As in other vascular territories, we do not know and have no biomarkers to decide 
which stenosis will progress to cause thrombosis, which stenosis if dilated will pre-
vent thrombosis, which stenosis once dilated will suffer early recurrence, which is 
the best option to prevent recurrence, and how to define the successful angioplasty.
4. Vascular access malfunction detection
In hemodialysis vascular access management, just as in general medicine, an 
early diagnosis of malfunction and prevention of definite failure is considered the 
best approach to diminish morbidity and costs. This axiom was strongly suggested 
in several seminal studies [10, 11] and is expressed in most guidelines of scientific 
societies in this field.
It is recommended that regular monitoring of access function should be 
performed, preferably by measuring vascular access flow (Qa), and when access 
stenosis is present, preemptive intervention should be performed percutaneously 
without further delay. In support of these level 2 recommendations, we can quote: 
“All types of pressure measurement should be abandoned in favor of access flow 
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measurement,” and “Monitoring plus intervention reduces thrombotic rates, 
morbidity and costs” [11, 12].
Consensual recommendations for preemptive intervention in malfunction-
ing grafts are (a) Qa measurement <600 ml/min for grafts or <400 ml/min for 
native fistulas and (b) a Qa drop higher than 25% over two consecutive measure-
ments [13].
However, recent and quite relevant information has questioned those recom-
mendations, and scanning through recent prospective randomized controlled trials 
in this field reveals some discordant opinions.
No matter if we are looking at native fistulas or PTFE grafts, using only Qa 
measurements, or its association with Doppler studies or dynamic venous pressure 
as surveillance techniques, it is believed that VA stenosis is now very effectively 
detected and responsible for a large increase in percutaneous vascular access 
procedures. Surprisingly, however, it has been found that all these diagnostic and 
therapeutic procedures fail to reduce the thrombosis rate or prolong access longev-
ity, fueling an ongoing controversy regarding its beneficial effects, both in terms of 
overall access survival and associated costs [6, 8, 14–20].
All presently approved clinical guidelines recommend performing surveillance 
of vascular access quality and performance, aiming at early detection of access 
stenosis, which induced a global trend toward implementation of Qa-based moni-
toring programs in many dialysis units.
The recommended Qa thresholds for angiography referral are based on its puta-
tive predictive power of access malfunction and/or failure.
However, even before the final decision on the clinical relevance of periodic Qa 
determination, the quality and accuracy of the Qa measurements methods must 
be questioned, as most techniques have a good correlation among them, but high 
variation in absolute terms (±200 ml/min) [21–30].
We are now in a position where we feel that we must do some form of VA sur-
veillance, but do not know exactly which. Qa, although not perfect, with results that 
are hard to interpret and need specific calibration to fine tune appropriate alarm 
thresholds for each measurement technique, is probably the best hemodynamic 
parameter to follow.
In our unit, we evaluate monthly Qa, together with a trend analysis of other 
equally not perfect parameters, like physical examination [31], Kt/V in all dialysis 
treatments, recirculation, and maximum obtainable Qb with circuit arterial pres-
sure above −250 mmHg, and then decide empirically, as physicians always do, when 
to refer to angiography.
A successful program of surveillance should reduce thrombosis rate by an 
amount identical to the angioplasty rate it induces. The key to measure surveillance 
effectiveness is avoidance of thrombosis; no other surrogate is acceptable.
As a matter of fact, absolute flow (Qa) and drop in flow, measured using 
several different flow indicators (ultrasound, thermal dilution, ionic dilution), 
are inaccurate predictors of thrombosis. Most thromboses are unpredictable, and 
interventions based on surveillance likely yield many unnecessary procedures at 
high cost.
We do not know if a vascular access defined by us as well functioning actually 
looks normal in angiography. Without that, it is difficult to really appreciate the 
specificity of our monitoring indicators and, most of all, the meaning of stenosis in 
the natural history of the VA.
Our data suggest that the presence of what we call a significant stenosis is not 
correlated with measured Qa and it might not be associated with early thrombo-
sis deserving immediate intervention [20]. Further studies are needed to clarify 
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the best surveillance protocol and the role of preemptive intervention in signifi-
cant stenosis.
A proposal for surveillance could well include the following:
A. Each unit should perform sequential measurement and trend analysis of the 
parameters of their choice.
B. Physical examination done and recorded before each dialysis by the R.N., in an 
access without dressings and needles. Signs to be looked for include a pounding 
pulse, an intermittent thrill, arm swelling, increment in collateral veins, dif-
ficult hemostasis, a new or an enlarging aneurysm, and pain during treatment, 
reaching an agreement rate with angiogram to detect stenosis of 80% [31].
C. Access flow measurement (Qa) in:
i. High-risk grafts—Every 2 weeks.
ii. Other grafts—Quarterly.
iii. Native fistulas with a Qa < 1000 ml/min—Quarterly.
iv. Native fistulas with a previous Qa ≥ 1000 ml/min—Once a year or whenever 
clinically indicated.
We consider high-risk grafts:
a. “Last” available vascular access site of that patient.
b. Frequent clotter.
c. Frequent recurrence of significant stenosis (less than 3 months apart).
Patients are referred from the dialysis unit to our VAC by their nephrologists, the 
indication for intervention is confirmed upon arrival, and an ultrasound/Doppler 
study will be performed if needed, to decide if it should be referred to the surgical 
or endovascular arm of the VAC and to help planning the endovascular approach 
localizing eventual stenotic lesions, their location, and preferred puncture site.
Our referral criteria to surgery: (a) Native AVF thrombosis; (b) VA rupture; 
(c) infection with visible abscesses or purulent discharge at puncture sites; (d) need 
for a new VA; (e) steal syndrome, VA limb distal ischemia; (f) primary malfunction 
of a VA created or submitted to open surgery less than 1 month ago; (g) growing 
aneurysm; and (h) hemorrhage.
Referral criteria to endovascular intervention: (a) Growing edema of the VA 
limb, (b) VA pain during dialysis treatment, (c) recent increment of VA venous 
pressure associated with a drop in dialysis adequacy, (d) unexplained drop in dialy-
sis adequacy, (e) a drop of VA flow (Qa) in 2 measurements <600 ml/min in a AVG 
or <400 ml/min a nAVF, (f) need for assisted maturation of a nAVF, (g) superior 
vena cava syndrome, and (h) AVG thrombosis.
The techniques we perform in the angiography suite are (a) diagnostic angi-
ography in no more than 7% of all cases, (b) percutaneous angioplasty (PTA) of 
stenotic lesions, (c) thrombolysis for thrombosed AVGs, and (d) stenting of elastic 
or frequently relapsed stenosis.
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In our unit, prospective results of 1-year follow-up in 71 new AV grafts with 
monthly surveillance revealed the following:
a. A Qa < 600 ml/min had the same predictive value with that ΔQa of 25%, and 
dynamic venous pressure was useless.
b. After 1 year only 35% of PTFEs did not need any kind of intervention. We 
demonstrated then a sensitivity of 82% and a specificity of 90% to detect 
stenosis.
c. “Successful” PTA in 91% and Qa↑ on average 142%.
d. A sensitivity of 39% and a specificity of 21% to detect thrombosis.
e. A thrombosis rate—0.46 thru/pt. year.
f. In 60% of cases, previous monitoring was normal.
5.  Endovascular intervention to correct dialysis vascular access 
malfunction
The initial treatment recommended for stenotic lesions in both nAVF and AVG 
is endovascular intervention, primarily angioplasty. Endovascular intervention is 
employed to maintain or even rescue AV access [38].
The recommendation within the K/DOQI guidelines is to treat hemodialysis access 
stenosis of more than 50% of the vessel lumen, if those are related with reduced flow 
rate and high venous pressure. PTA is considered a standard of care in failing hemodi-
alysis access due to its high rates of success and satisfactory patency rate [37].
5.1 Stenosis location
The stenotic lesions in an AV fistula can occur in any location of the access 
system, with a higher incidence in specific spots for each type of VA. This is the 
case of stenosis at the proximal “swing segment” (the vein segment immediately 
after the arteriovenous anastomosis of a nAVF, which was dissected and brought 
close to the artery to create the anastomosis) either in the upper arm in transposed 
brachio-basilic fistulas, or in the lower forearm, in radio-cephalic fistulas, which are 
relatively more frequent than lesions at any other site [36]. Another example is the 
cephalic arch region, in patients with brachiocephalic fistulas [38].
Below we describe some types of stenosis of the vascular circuit, selected for 
their particularities, namely, their frequency, risk of restenosis, and predictable 
danger of VA failure.
5.2 Cephalic arch stenosis
The proximal cephalic vein is characterized by a curved shape, which occurs as 
the cephalic arch passes though the coracoclavicular ligament, just before joining the 
subclavian vein.
Several reasons have been put forward to justify the development of cephalic 
arch stenosis, such as increased blood flow rates, hemodynamic factors associated 
with the vessel shape, external compression by the outer structures surrounding the 
vein, and hypertrophy of valves that are often present in the cephalic arch.
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Although angioplasty is the accepted initial treatment of cephalic arch stenosis, 
it can be problematic because lesions in that location are more resistant to dilatation. 
When dealing with resistant stenotic lesions, it is shown that employing cutting bal-
loons (see below) may improve outcomes. On the other hand, complications are more 
likely (vein rupture), and patency is reduced compared with other vein location. Stent 
placement in the arch is a delicate task because the stent should invade the subclavian 
vein lumen, which can result in its partial or total occlusion, impeding the future cre-
ation of an AVF or AVG using the basilic or axillary vein, thereby consuming vascular 
patrimony. In view of the recurrent problems with angioplasty of the cephalic arch, 
the stent placement can be an alternative to rescue the vascular access (Figure 1).
For several reasons, it is not possible to make any evidence-based recommenda-
tions on best practices for management of CAS (endovascular or surgical). There 
is profound heterogeneity in the studies retrieved, from their initial design to their 
presentation of data. Few studies were prospective, few studies involved more than 
one or two centers, and the lack of uniformity of outcomes is another weakness of 
current published studies. CAS is often managed alternatively by interventionists 
and surgeons, in our experience with identical success.
5.3 Central vein stenosis
The prior placement of a central venous catheter is by far the most common 
cause of central vein stenosis (CVS) in dialysis patients. Transvenous wires of 
cardiac rhythm devices are more and more related with central veins stenosis in this 
population of high cardiovascular morbidity. Hemodialysis patients are, therefore, 
primary candidates for new wireless pacemakers or epicardial pacemaker leads.
The surgical approach to central vein stenosis is difficult because they can hide 
behind the bone structure. Therefore, endovascular intervention with angioplasty 
and/or stent placement becomes a logistically more receptive proposal for treatment 
of CVS. Still, anatomically and functionally, central veins have several specific 
characteristics including the diameter, angle, and elasticity that make treatment 
and maintenance of their patency after intervention difficult.
Some central vein stenoses are not symptomatic. Asymptomatic central veins 
stenosis, involving less than 50% of the vessel lumen, does not require treatment 
and is best managed by simple supervision [39].
Angioplasty with or without stent placement has been the recommended 
preferred approach to CVS. The guideline 20 NKF-K/DOQI suggests that the 
percutaneous intervention with transluminal angioplasty is the preferred treatment 
for CVS [44]. PTA has very high initial technical success rates, ranging from 70 to 
90% [40, 41]. Primary and cumulative patency rates are widely variable and can 
Figure 1. 
(a) and (b). Stenosis affecting cephalic arch; this lesion responded well to balloon angioplasty.
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Figure 2. 
(a) Right brachiocephalic trunk stop flow. (b) PTA of stenosis with 12 mm balloon. (c) Final angiogram result.
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range between 23 and 63% at 6 months and 12 and 50% at 12 months in the case 
of primary patency rate, as well as 29 and 100% at 6 months and 13 and 100% at 
12 months in the case of cumulative patency rate (Figure 2) [42–46].
Our cumulative experience shows that angioplasty and stent placement is under-
mined by frequent and rapid recurrence. It can also happen that an asymptomatic 
lesion can become symptomatic upon intervention. Indeed, one study showed that 
stenosis can progress faster after intervention [40]. The venous response may be 
worsening, and the stenosis process can be accelerated due to angioplasty.
Correction of CVS with endovascular approaches remains therefore limited 
and suboptimal and may even be harmful in certain cases. After angioplasty, more 
aggressive neointimal hyperplasia and proliferative lesions were found in restenosis 
areas than in the original stenotic lesions [41].
A major problem with lesions in the central veins is that many are quite elastic. 
For this reason, endovascular stents are used more frequently for central veins ste-
nosis than for other types of dialysis access lesions. Cost considerations are highly 
relevant and also the fact that we are left without any option to treat effectively a 
restenosis inside a stent. Even if we extend 100% the half-life of a recurrent stenotic 
access (from a procedure every 3 months to every 6 months), it may look as an 
impressive achievement, but with little clinical relevance.
5.4 Juxta-anastomotic location
The vein immediately adjacent to the arteriovenous anastomosis (commonly 
referred to as juxta-anastomosis) is a common location of stenosis. This is in part 
due to injury, which occurred while “swinging” the vein to form the AV anastomo-
sis. Some studies demonstrate that the frequency of juxta-anastomotic stenosis may 
be up to 55% [47].
Angioplasty and surgery are two treatment options. Percutaneous angioplasty 
has 1-year patency rates of 44–79% [48–50]. For surgery, 1-year patency rates are 
between 64 and 88% [49–51]. In this location, we usually need very high-pressure 
balloons to deal with very hard lesions. If we elect a surgical solution, we get better 
results at the expense of a few more centimeters of vascular territory. Regrettably, 
randomized studies comparing endovascular treatment and surgery for this lesion 
are not available (Figure 3).
5.5 Type of angioplasty balloons
There are several types of balloons that we can use in angioplasty: (i) “high-
pressure,” (ii) “ultrahigh-pressure (UHP),” (iii) “cutting,” and (iv) “drug-eluting.”
5.5.1 High-pressure balloons
High-pressure, noncompliant balloons (e.g., Conquest from Bard Peripheral 
Vascular Inc., Tempe, Arizona) have rated burst pressures of 20 to 24 atm and are 
used to treat dialysis vascular access stenosis.
5.5.2 Ultrahigh-pressure balloons
Venous stenosis is characterized by extensive fibrosis and the need for ultrahigh-
pressure balloon inflations [52] or cutting balloon atherotomy for optimal treat-
ment [53, 54].
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An UHP balloon is certified for a burst pressure of 27 atm, but higher inflation 
pressures are possible. Although those balloons do not provide better results in terms 
of permeability, when compared to conventional ones, it has been suggested that 
such devices may achieve better patency rates than traditional HP angioplasty bal-
loons [55]. Its use is indicated in the treatment of symptomatic stenosis not respond-
ing to conventional high-pressure balloon. The high price of UHP balloon, the need 
for use thicker inserts, the difficulty of emptying, and its lower compliance and 
flexibility make it advisable that UHP balloons should not be a first choice in stenosis 
treatment.
Despite that, ultrahigh-pressure balloons have significantly reduced the inci-
dence of “resistant” lesions [56].
5.5.3 Cutting balloons
The cutting balloons are special angioplasty balloons with three or four cutting 
edges (atherotomes) fixed longitudinally to its surface. The atherotomes expand 
radially with balloon inflation and provide longitudinal incisions into the lesion 
cutting into tenacious neointima. Using cutting balloons has the advantage that 
disruption of the lesion occurs in a more controlled manner and at lower balloon 
inflation pressure than with conventional angioplasty.
The use of a cutting angioplasty balloon (CAB) to treat resistant lesions can be 
found in several reports [53, 55]. Most of these reports are constrained because 
they are retrospective, lack control, or the size is too small to allow meaningful 
Figure 3. 
(a) Severe stenosis in juxta-anastomotic radio-cephalic fistula. (b) Angiogram result after angioplasty with 
7 mm PTA balloon.
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conclusions. Taking into account the data reported in the literature and also consid-
ering the authors experience, it can be stated that angioplasty with a cutting balloon 
is safe and can be considered as an alternative treatment for stenosis of hemodialy-
sis AVFs that do not respond to conventional balloons.
There are serious methodologic limitations in the published reports describ-
ing the use of cutting balloon angioplasty to treat hemodialysis vascular access 
stenosis [57–60]. Studies include the concurrent use of cutting and conventional 
balloon angioplasty, the use of a high-pressure balloon, or a combination with 
placement of a stent after cutting balloon angioplasty. In other studies, cutting 
PTA was used only after the failure of high-pressure balloon angioplasty. In these 
reports, the long-term patency rate does not reflect the results obtainable with 
cutting balloon angioplasty as a primary, stand-alone treatment. The cutting 
balloon was designed primarily to reduce vascular trauma, thereby diminish-
ing neointimal hyperplasia, thereby improving hemodialysis access long-term 
patency. It should be noted that studies comparing cutting balloon and conven-
tional balloon angioplasty in the treatment of vascular access stenosis are fraught 
with conflicting results.
5.6 Drug-coated balloons
Good results have been obtained with drug-coated balloon (DCB) angioplasty 
used to prevent restenosis in the treatment of arterial stenosis. This approach (using 
paclitaxel-coated balloons) was extended to the treatment of stenosis associated 
with hemodialysis AV access, with mixed results [61].
Drug-coated balloon endovascular technology merges the dilating properties 
of angioplasty with local drug delivery. Balloon surface excipients enable drug-
eluting within the vessel wall, inhibiting cell proliferation, and reducing neointimal 
hyperplasia, while avoiding the use of permanent metal stents.
DCB angioplasty of vascular access stenosis seem to be safe and effective, providing 
superior reintervention-free intervals compared to conventional plain balloon angio-
plasty [62–64]. Recently, Yan and others published a meta-analysis that reveals that 
DCB is an effective and safe method that can significantly prolong 6-month and 1-year 
target lesion primary patency for failing hemodialysis access, as compared to conven-
tional plain balloon angioplasty. However, their study was limited by the small number 
of patients enrolled in each trial, the diversity characteristics of the lesions, the vintage 
of the dialysis access, and the formulations of paclitaxel (different dose or excipients 
used). A very heterogeneous group of studies lumped together [65].
The reported number of dialysis patients treated with DCBs is low, and several 
concerns remain unanswered. First of all, it is uncertain which lesions will ben-
efit from the use of this balloon device. Lesion preparation is another issue that 
deserves further investigation. Manufacturing companies suggest pre-dilation with 
a shorter balloon, with the same diameter, to promote drug diffusion within the 
deeper layers of the vessel wall and to improve the restenosis rate. However, in some 
RCTs published, pre-dilation was not even performed. Last but not least, although 
the long-term safety of PCBs in dialysis access treatment has been proven, preclini-
cal and experimental studies in animal models are lacking; consequently, we have 
no available information on the posttreatment lesion pathology, degree of drug 
diffusion, and the extent of paclitaxel fixation within the venous wall.
It should be noted that the use of drug-eluting balloons is a novel medical 
device that aims to decrease the trauma in the endothelium of the vascular wall of a 
fistula. Although more expensive than the conventional balloon, it is much cheaper 
than a bare metal stent, and repeated procedures can be performed in case of 
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recurrences. More trials are needed to find out if this more expensive material can 
really increase the patency of venous lesions.
5.7 Stent placement
Several challenges must be faced by resistant or recurrent stenosis throughout 
the access circuit in terms of providing optimal hemodialysis treatment. Those 
stenoses can be successfully treated by endovascular stent placement, although it 
usually requires multiple procedures to maintain patency.
Indeed, bare metal stents and covered stents have emerged as a potential addi-
tional therapeutic intervention in vascular access dysfunction. However, results are 
not encouraging. For example, bare stents are seldom used due to a high incidence 
of in-stent stenosis, and covered stents also have problems.
There are three mostly accepted indications for stent deployment: (i) a stenotic 
lesion that recurs within a 3-month period after initially successful balloon angioplasty 
in a patient with exhausted VA sites, (ii) a stenotic lesion with high elastic recoil (usu-
ally in central veins), and (iii) rupture of an outflow vein after balloon angioplasty 
that cannot be handled using more conventional actions (balloon tamponade). Other 
special conditions where a stent implantation should be considered include (i) venous 
outflow stenosis, (ii) pseudo-aneurysms, and (iii) cephalic arch stenosis.
We must take special care not to occlude important collateral veins with 
implanted stent, namely, the homolateral internal jugular vein, always required for 
future central vein catheters.
There are several reported complications associated with stent placement, such 
as stent migration, or stent fracture, which is usually seen on control angiograms. 
Infection is also a significant complication with potentially tragic outcomes. It 
should be noted that the combination of the immune-compromised status of 
patients with ESRD and repetitive cannulations for dialysis treatments is likely fac-
tors leading to infection. One unique complication is stent struts protrusion, which 
results from placing stents in cannulation sites [66]. Damage of the metal part of 
the stents (struts) can result from repetitive cannulation.
The high cost of stents has to be taken into account, raising the question whether 
the benefits obtained by placing stents at stenotic lesions outweigh the costs associ-
ated with such treatment [9]. One should reflect if the option of creating a secondary 
AVF should be considered as an alternative treatment for placing a stent (Figure 4).
5.8 AVG thrombolysis
Graft thrombosis occurs in one-third of all AVG per year, and of those that 
thrombose, 60% have more than two episodes per year. Ninety percent of all 
AVG thrombosis are associated with a stenotic lesion, most commonly in the 
venous anastomosis, but can occur in any location, in 36% of the cases in more 
than one site.
In our VAC, AVG thrombosis is primarily referred to interventional nephrology 
for endovascular thrombectomy, combining pharmaco-mechanical thrombolysis 
with a multiperforated catheter occluded at its tip, allowing high-pressure lateral 
injection of heparinized saline to dislodge wall adherent clots, followed by angio-
plasty with a 8 mm balloon of all stenotic lesions and finally embolectomy of the 
arterial anastomosis with a 4 French Fogarty catheter, to remove a more adherent, 
residual, fibrin “white” clot. Alternatively, some of us may use a mechanical device, 
the Arrow-Trerotola©, that combines clot fragmentation and aspiration, adding 
quite a substantial extra cost, without improving outcomes.
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The procedure should not be performed if the AVG is suspected to be infected 
or a graft rupture is detected. At the end of the procedure, we must check AVG 
flow, the presence of residual clot inside the VA, and the most dreadful complica-
tion, symptomatic hand ischemia due to distal arterial embolization, which must 
be resolved with embolectomy in the angiographic suite or urgently referred to 
surgery.
6. Endovascular intervention outcomes
The quality indicators achieved in our VAC include: (a) creation of a nAVF as 
first access in 80% of all patients and in 60% of subsequent accesses, (b) less than 
40% primary failure of nAVF at 3 months, (c) less than 55% secondary failure of 
nAVF at 12 months, (d) less than 30% primary failure of AVGs at 3 months, (e) per-
cent of functioning AVG post-thrombolysis >75% at 7 days and >50% at 3 months, 
and (f) no VA infections 15 days post-intervention. Regarding VA, the dialysis 
unit quality indicators are (a) percent of prevalent patients with nAVF >65%, (b) 
percent of patients with long-term tunneled catheters <20%, and (c) referral’s rate 
to the VAC <0.8/patient years.
Figure 4. 
(a) Stop flow at right BCT. (b) Placement of a stent. (c) Angiogram after 12 mm PTA balloon. (d) Final 
angiogram result.
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The technical details of all procedures we perform in our VAC are thoroughly 
described in a recent textbook [33, 34].
The National Kidney Foundation (KDOQI) guidelines [35] define a successful 
angioplasty a residual stenosis <30%, with return to acceptable levels of the parame-
ters used to place the indication for angioplasty. Initial success rates using anatomical 
criteria ranged from 80 to 98%, but in some reports, 20–30% of these patients with 
anatomical success fail to increase blood flow (residual stenosis, a missed lesion, or 
elasticity). Primary patency rates are 41–76% at 6 months and 31–45% at 1 year.
Long-term primary patency rates for thrombectomy are not as good as for 
angioplasty; therefore every effort should be made to prevent thrombosis by the 
prospective diagnosis and treatment of venous stenosis.
In a thrombosed access, the treatment must be timely to avoid catheters, done 
as an outpatient, venous stenosis must be detected and corrected, hemodynamic 
parameters should return to baseline, and patient should be evaluated for a second-
ary arteriovenous native fistula, created using upper arm veins that have become 
dilated because of the functioning graft.
In 2019, 139 surgical thrombectomies were performed in 127 patients (69 in 
nAVF and 70 in AVG). In 49.6%, no new intervention was required, and the 
average time until a new intervention was 46.7 days. Primary patency at 1 month 
was 66%, at 3 months 54.4%, and at 6 months 17.5%. In that same period, the 
angiography suite received 134 patients for 179 procedures (171 in AVGs, 8 with 
a nAVF), there was immediate success in 159 patients, the average time until a 
new intervention was 58.1-day, and primary patency at 1 month was 71.6% and at 
6 months 42.5%. In our case, Qa average improvement is >50%, and we expect a 
Kt/V above 1.4.
In intervening in a nAVF, use when available ultrasound localization of stenosis to plan the best place and 
direction to puncture the access
In intervening in a AVG, always puncture close to the arterial anastomosis in the direction of the flow toward 
the venous anastomosis
Use a 7F sheath and a hydrophilic guide wire. It allows balloons up to 14 mm to be inserted more than once
Do not miss any step even when it seems unnecessary. Always check AV anastomosis in nAVFs and arterial 
and venous anastomosis in AVGs, as well as central venous drainage
Do not accept incomplete balloon dilation. If necessary, use high-pressure balloons or cutting balloons
Avoid stents, only as a last resort
In AVG thrombolysis, after dealing with the venous anastomosis, even if the graft is already working, do 
approach with a Fogarty the arterial anastomosis
Always test flow at the end of a procedure. An eyeball test as the TIMI for cardiologists. If flow does not look 
great, it is because there is something else to fix
Table 2. 
Clinical pearls to take home.
Procedures At 30 days 
(%)
At 90 days 
(%)
At 180 days (%)
Diagnostic angiography 83 55 45
Angioplasty 92 60 45
Thrombolysis + angioplasty (AVG) 86 51 40
Table 1. 
Primary patency in our VAC at 30, 90, and 180 days, in line with most literature in the field.
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The immediate success rate of thrombolysis should be 85% or greater accord-
ing to the NKF/KDOQI guidelines and the primary (unassisted) patency goals at 
3 months at least 40% (Tables 1 and 2).
7. Conclusion
In conclusion, we are still dealing with quite a number of known unknowns. 
There has been no RCT to elucidate which percentage of lumen compromise should 
dictate the indication for angioplasty, and most operators choose 50%. Not all ste-
notic plaques were created equal, and some will never progress, but we cannot guess 
which ones. We also have no proof that a successful PTA in a graft improves long-
term patency rate [14], angiographic criteria to assess the success of angioplasty are 
not predictive of changes in blood flow, and there is no correlation between changes 
in blood flow and changes in the percent of stenosis post-PTA [32]. In an era 
characterized by less is more, under the imperative of being useful for our patients, 
creating long-term solutions at sustainable costs, we feel a desperate need for robust 
scientific evidence to support our decision process and the procedures we perform. 
Just because it can be done, does not mean it should be done, our intervention is no 
more a question of know-how, but of know-when.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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